论文部分内容阅读
司帕沙星(Sparfloxacin)是一种喹诺酮类新药,对革兰氏阳性菌,如葡萄球菌、链球菌和肠球菌具有广谱,强效的抗菌活性。特别是对革兰氏阴性菌,如肠道细菌、假单孢菌属和流感嗜血菌,以及各种枝原体、军团菌、衣原体和分枝杆菌均显示强大的抗菌作用。司帕沙星对革兰氏阳性菌的抗菌活性超过环丙沙星或氟罗沙星,并且它对肠道细苗族和非发酵菌的抗菌活性与环丙沙星和氟罗沙星一样有效。小白鼠肾脏溃疡模型实验证实了司帕沙星的有效性,并与氟罗沙星作了对比。
Sparfloxacin is a quinolone novel drug that has broad-spectrum, potent antibacterial activity against gram-positive bacteria such as staphylococci, streptococci and enterococci. In particular, Gram-negative bacteria, such as intestinal bacteria, Pseudomonas and Haemophilus influenzae, and various Mycoplasma, Legionella, Chlamydia and Mycobacterium showed a strong antibacterial effect. Sparfloxacin exerts more antimicrobial activity against Gram-positive bacteria than ciprofloxacin or fleroxacin, and its antibacterial activity against gut-specific and non-fermentative bacteria is as effective as ciprofloxacin and fleroxacin. Mouse model of renal ulcer model confirmed the effectiveness of sparfloxacin, and compared with fleroxacin.